The PROBE trial (NCT04510597), due in 2033, will compare deferred CN versus no CN in patients receiving upfront nivolumab, pembrolizumab-axitinib, or avelumab-axitinib.
Hosted on MSN11mon
Kidney cancer treatments and tumor biology can activate different immune-modifying processes in patientsAn analysis of blood and tumor samples from patients in a clinical trial comparing two therapies for advanced renal cell carcinoma shows that different immunomodulatory mechanisms are at work ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback